RedDress Announces Launch of ActiGraft, FDA-Cleared for the Treatment of Chronic and Acute Wound Types

Once applied, ActiGraft serves as a protective covering, biologic scaffold and wound microenvironment to promote the natural wound healing processes of the body. ActiGraft recently received 510(k) clearance from the U.S. Food and Drug Administration (FDA).

We're incredibly proud to introduce ActiGraft to the wound care community, said Alon Kushnir, Founder and CEO of RedDress. There's an estimated 6.5 million people in the U.S. suffering from severe, debilitating wounds and ulcers; the development of a treatment that replicates one's own natural healing process was our solution to address the community's unmet need and transform the way health care providers, patients, and their caregivers, manage hard-to-treat wounds and ulcers.

ActiGraft supports each stage of the wound healing process and delivers significant benefits in terms of comfort, effectiveness, and cost. These benefits include

Significantly faster healing with less wound interaction and reduced patient pain
Once per week application process saves facility staff time
Requires no capital equipment, tissue banking, HCT/P or TJC regulatory requirements
Short learning curve to implement and use
Effective tool for Facilities to improve quality scores

ActiGraft can be used for a wide variety of hard-to-treat chronic and acute wounds, including but not limited to

Diabetic/Neuropathic Ulcers
Pressure Ulcers/Injury
Venous Stasis Ulcers
Post-Surgical Wounds
Traumatic Wounds
Skin Tears